XASXCMP
Market cap30mUSD
Jan 08, Last price
0.27AUD
1D
-1.85%
1Q
-18.46%
Jan 2017
-69.54%
Name
Compumedics Ltd
Chart & Performance
Profile
Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Okti; Grael PSG; Grael DC; Somfit/Somfit Pro, a wearable device; TCM5 FLEX Transcutaneous monitor; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that provides integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, and persyst software products. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited operates as a subsidiary of D & DJ Burton Holdings Pty Ltd.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | ||||||||||
Revenues | 49,719 17.24% | 42,408 12.32% | 37,756 5.64% | |||||||
Cost of revenue | 50,531 | 45,942 | 37,619 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (812) | (3,534) | 137 | |||||||
NOPBT Margin | 0.36% | |||||||||
Operating Taxes | 818 | (597) | 341 | |||||||
Tax Rate | 248.91% | |||||||||
NOPAT | (1,630) | (2,937) | (204) | |||||||
Net income | (338) -94.48% | (6,122) -551.14% | 1,357 35.97% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 7,752 | 7,906 | 6,169 | |||||||
Long-term debt | 2,427 | 2,915 | 532 | |||||||
Deferred revenue | 34 | 76 | 145 | |||||||
Other long-term liabilities | 36 | 67 | 54 | |||||||
Net debt | 7,637 | 6,321 | (1,806) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 2,001 | 49 | 3,287 | |||||||
CAPEX | (313) | (4,408) | (2,985) | |||||||
Cash from investing activities | (2,987) | (4,408) | (2,985) | |||||||
Cash from financing activities | (1,490) | (1,005) | 1,615 | |||||||
FCF | 712 | (568) | 348 | |||||||
Balance | ||||||||||
Cash | 1,890 | 3,797 | 7,294 | |||||||
Long term investments | 652 | 703 | 1,213 | |||||||
Excess cash | 56 | 2,380 | 6,619 | |||||||
Stockholders' equity | 18,210 | 18,291 | 23,591 | |||||||
Invested Capital | 26,802 | 24,165 | 23,719 | |||||||
ROIC | ||||||||||
ROCE | 0.45% | |||||||||
EV | ||||||||||
Common stock shares outstanding | 177,163 | 177,163 | 177,163 | |||||||
Price | 0.34 86.11% | 0.18 16.13% | 0.16 -60.76% | |||||||
Market cap | 59,350 86.11% | 31,889 16.13% | 27,460 -60.76% | |||||||
EV | 66,987 | 38,210 | 25,654 | |||||||
EBITDA | 758 | (2,521) | 1,349 | |||||||
EV/EBITDA | 88.37 | 19.02 | ||||||||
Interest | 739 | 652 | 401 | |||||||
Interest/NOPBT | 292.70% |